Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Other Non-Current Assets (2016 - 2025)

Cardiff Oncology's Other Non-Current Assets history spans 15 years, with the latest figure at $549000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 695.65% year-over-year to $549000.0; the TTM value through Dec 2025 reached $549000.0, up 695.65%, while the annual FY2025 figure was $549000.0, 695.65% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $549000.0 at Cardiff Oncology, roughly flat from $549000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.4 million in Q2 2023 and bottomed at $69000.0 in Q4 2024.
  • The 5-year median for Other Non-Current Assets is $475000.0 (2025), against an average of $694100.0.
  • The largest annual shift saw Other Non-Current Assets crashed 94.61% in 2024 before it skyrocketed 695.65% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $239000.0 in 2021, then skyrocketed by 480.33% to $1.4 million in 2022, then decreased by 7.79% to $1.3 million in 2023, then plummeted by 94.61% to $69000.0 in 2024, then surged by 695.65% to $549000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Other Non-Current Assets are $549000.0 (Q4 2025), $549000.0 (Q3 2025), and $401000.0 (Q2 2025).